CPT 81218 CEBPA Full-Gene Sequencing Reimbursement

CPT code 81218 represents full-gene sequencing of the CCAAT/enhancer binding protein alpha gene (CEBPA), a targeted molecular diagnostic assay used primarily in hematology to identify pathogenic variants that can affect diagnosis, prognosis, and therapeutic choices. Nationally, gene sequencing codes like 81218 are central to precision medicine programs, oncology workflows, and laboratory reimbursement discussions because they combine technical sequencing work with complex interpretation needs.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage patterns and policy considerations for genetic testing reimbursement across major payers, along with typical sites of service and clinical context where CEBPA sequencing is ordered. The publication outlines benchmark topics such as payment categories for molecular diagnostics, common billing modifiers used with lab services, and how full-gene sequencing fits into diagnostic algorithms for blood disorders. It also summarizes policy updates affecting molecular testing authorization and clinical documentation requirements. This resource is intended to help billing professionals, laboratory managers, and policy analysts understand the code’s clinical role, payer landscape, and the operational context for ordering and processing CEBPA full-gene sequencing.

Billing Code Overview

CPT code 81218 describes laboratory analysis that sequences the entire coding region of the CCAAT/enhancer binding protein alpha gene (C/EBP alpha; CEBPA). This service is a molecular diagnostic test that detects sequence variants across the full gene to inform diagnosis, prognosis, and treatment decisions in hematologic and other conditions.

Service type: Full gene sequencing / molecular genetic testing
Typical site of service: Clinical molecular laboratory or hospital laboratory (technical component performed by a lab analyst)

Clinical Context

A 58-year-old adult with newly diagnosed acute myeloid leukemia (AML) undergoes molecular testing to characterize somatic mutations that guide prognosis and therapy. The hematologist/oncologist orders full gene sequencing of the CCAAT/enhancer binding protein alpha gene (CEBPA) to detect single-nucleotide variants, insertions/deletions, and multilocus mutations. A peripheral blood or bone marrow specimen is collected in an appropriate preservative and sent to a molecular diagnostics laboratory. The laboratory performs nucleic acid extraction, library preparation, next-generation sequencing (NGS) or Sanger sequencing as appropriate, bioinformatic analysis, and interpretation to determine the entire coding sequence of CEBPA. Results are reported to the ordering clinician and incorporated into treatment planning, risk stratification, and consideration for targeted therapies or hematopoietic stem cell transplant.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing for the professional interpretation component separate from the lab technical component.
`TC`

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology	Hematologists order and interpret `CEBPA` testing for leukemia diagnosis and management.
`207RP1001X`	Medical Oncology	Medical oncologists use mutation data for AML prognostication and therapy selection.
`207L00000X`	Clinical Pathology	Pathologists and laboratory directors oversee molecular testing quality and reporting.
`337Q00000X`	Molecular Genetic Laboratory	Laboratory specialists performing molecular diagnostics and sequencing.
`208000000X`	Internal Medicine	Hospitalists or internists may request testing as part of initial hematologic workup.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C92.0`	Acute myeloblastic leukemia with maturation	`CEBPA` sequencing is indicated for AML subtyping and prognostic assessment.
`C92.1`	Acute myelogenous leukemia without maturation	Molecular testing for `CEBPA` mutations informs treatment decisions across AML subtypes.
`D47.1`	Chronic myeloproliferative disease	When transformation or atypical features occur, `CEBPA` testing can assist in differential diagnosis.
`D46.9`	Myelodysplastic syndrome, unspecified	In cases with suspected progression toward AML, `CEBPA` mutation status may be evaluated.
`Z15.0`	Genetic susceptibility to malignant neoplasm; familial genetic carrier, documented	Germline `CEBPA` mutations can confer familial predisposition; full gene sequencing evaluates hereditary variants.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81218`	CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA), gene; full gene sequence analysis	Primary procedure representing sequencing of the entire `CEBPA` coding region.
`81445`	Oncology (somatic) sequencing; DNA, 5–50 genes	Panel-based somatic NGS that may include `CEBPA` as part of a broader myeloid mutation panel commonly ordered alongside single-gene testing.
`81225`	FLT3 (including TKD) full gene sequence analysis	Common companion molecular test in AML workups; results complement `CEBPA` for prognostic classification.
`81162`	Interpretation and report of sequence variants, germline or somatic, tier 1 or 2 (list or multigene panel)	Professional interpretation and reporting services that may be billed separately or bundled with sequencing when applicable.
`88360`	Microscopic examination, cytogenetic analysis (morphology directed) — data not typical for sequencing labs but may be performed in parallel	Cytogenetic and morphological studies are often performed in the diagnostic workflow along with molecular testing for comprehensive evaluation.

OpenPayer

Summary & Overview

CPT 81218: CEBPA (C/EBP Alpha) Full-Gene Sequencing